Tumoral DKK1 Expression as a Predictor of Clinical Benefit to DKN-01
Time: 11:30 am
day: Day 1 Track B AM
Details:
- DKK1 is overexpressed in many cancers, often leading to worse outcomes by promoting tumor growth, metastasis and contributing to an immunosuppressive tumor microenvironment
- DKN-01 in combination with standard of care therapies has demonstrated compelling clinical data with enhanced activity seen in DKK1-high patients
- DKK1 RNAscope CDx development to support the clinical development of DKN-01 is underway
